How much does Spravato cost?

Understanding the bill requires knowing that Spravato is not priced like a prescription. It is priced like a procedure that happens to involve a drug.

The medication

Esketamine is supplied as single-use nasal spray devices, each containing 28 mg. A 56 mg dose is two devices; an 84 mg dose is three. CMS's National Average Drug Acquisition Cost survey — which measures what pharmacies actually pay to acquire a drug, and is not the same thing as list price or wholesale acquisition cost — puts the acquisition cost at roughly $853 for a 56 mg dose and $1,289 for an 84 mg dose.

We quote NADAC rather than a list price deliberately. List price for this product is not something we could source to a citable published document, and quoting an unsourced figure on a page whose entire premise is honest sourcing would be self-defeating.

The administration and the two hours

Here is the part that catches almost everyone, including people who have researched carefully.

Medicare pays for a Spravato session under two codes — G2082 for doses up to 56 mg and G2083 for doses above it. Those codes are bundled: their official descriptors cover the provision of the medication together with the supervised administration and the observation period. The drug and the monitoring are not two separate line items you can add up.

This matters practically. If you find a drug price and a clinic fee and add them together, you will roughly double the medication portion and come out with a number substantially higher than reality. We got this wrong in an early version of the estimator on this page, which is why it is called out here rather than quietly fixed.

The associated visit

Some sites bill an evaluation and management visit alongside the session, particularly early in treatment when your prescriber is assessing response and adjusting dose. This is a separate charge, and it is a fair question to ask about in advance.

Why the split matters so much

Because Spravato is administered to you at a facility rather than dispensed to you at a pharmacy counter, it runs through the medical benefit. Your pharmacy benefit — the one with the tiered copays you are used to — is not involved.

That single fact is the most common source of a surprise bill on this treatment. People call their insurer, ask "do you cover Spravato", get routed to pharmacy benefits, hear a copay figure that sounds manageable, and then receive a medical-benefit bill with coinsurance and a deductible attached. The insurance page covers how to have that phone call properly.

Four routes, with their real eligibility rules rather than the marketing version.

The manufacturer savings programme

The SPRAVATO withMe Savings Program advertises paying as little as $10 per treatment for the medicine. Two conditions on that, both from the programme's own published terms:

• It is for people with commercial insurance only. The terms exclude anyone using a state or federal government-funded healthcare programme, naming Medicare, Medicaid, TRICARE, the Department of Defense, and the Veterans Administration. This is a federal restriction on manufacturer copay support, not a decision your plan made, so there is no appeal.
• It does not cover the treatment observation. The terms say so explicitly. The two-hour monitoring is typically the larger charge, and it sits outside the benefit. A programme that reduces your medicine cost to $10 has not reduced your session cost to $10.

The terms also note an annual maximum benefit without publishing a dollar figure for it, so confirm your remaining benefit with the programme directly rather than assuming.

Patient assistance, which has the opposite rules

The Johnson & Johnson Patient Assistance Program may provide the medication at no cost for up to a year to people whose household income is at or below 300% of the federal poverty level.

The important and widely missed detail: unlike the savings programme, patient assistance does not exclude people with government insurance. If you are on Medicare and were told copay support is unavailable to you, that is true of the savings card and not necessarily true of patient assistance. These are two different programmes with opposite rules on federal payers, and they are easy to conflate because the same company runs both. It does not cover the site's administration and monitoring fee.

HSA and FSA funds

Spravato is a prescribed medical treatment, so costs are generally eligible for payment from a health savings account or flexible spending account. This does not reduce the cost, but it pays it with pre-tax money.

Appealing a denial

Denials on documentation grounds are frequently resolvable, because the underlying problem is usually a records gap rather than a coverage decision. The insurance page covers the internal appeal and external review process.

We do not take referral fees, we do not run affiliate links, and there is nobody to call here to "see if you qualify". Everything above is something you or your prescriber's office can do directly.

The estimator's working, in the open, so anyone — including a clinic that disagrees with it — can check it.

The model. The bundled per-session amount comes from the CMS Physician Fee Schedule for 2026: G2082 at 28.52 non-facility total RVUs and G2083 at 40.60, at the file's conversion factor of 33.4009, giving roughly $953 and $1,356 nationally. We apply a ±15% band for geographic practice-cost adjustment. From there:

• Medicare Part B: the bundled amount × 20% coinsurance, with the 2026 Part B annual deductible of $283 applying first.
• Commercial: the bundled amount × a coinsurance band of 10–40% × a deductible-status factor. That coinsurance band is a general plan-design range, not a Spravato-specific figure — contracted rates are not public — which is why it carries our lowest confidence rating and produces our widest ranges.
• Cash: the bundled Medicare allowed amount, presented as a benchmark rather than a price, because no clinic publishes a standard self-pay rate for this.
• Medicare Advantage, Medicaid, VA/TRICARE, and commercial with the savings programme: no dollar figure at all. See below.

The rules that keep it honest. Per-session figures round outward to the nearest $25 and phase totals to the nearest $100 — the low bound down, the high bound up. If a computed range is narrower than 1.4 times its low bound, it is widened until it isn't, because a narrow range implies a confidence this model does not have. If a figure lands outside a sanity clamp, the number is suppressed rather than shown.

Where it refuses to answer. Four situations produce no number: Medicare Advantage (plan-specific copays and network rules dominate), Medicaid (state-by-state variation, though the general pattern of $0 to a few dollars is reliable and we say so), VA and TRICARE (access is a referral pathway, not a cost share), and commercial insurance with the savings programme (the programme covers the medicine but not the observation, and the observation fee is unpublished, so any figure would be mostly guesswork).

What is deliberately out of scope. Geographic adjustment beyond the ±15% band, because no citable per-market dataset exists. Named insurers' fee schedules, because contracted rates are not public. Any figure presented as what a specific clinic charges.

Every constant is dated and sourced, and the build fails if any of them goes more than 180 days without being re-verified. That is not a promise to keep this current — it is a mechanism that makes it impossible to quietly not.

If you think something here is wrong, tell us. Being corrected is cheaper than being wrong.